Variable | Healthy subjects (n = 10) | Long COVID-19 syndrome (n = 19)* | p-value |
---|---|---|---|
Age (years) | 51 ± 11 | 45 ± 13 | 0.20 |
BMI (kg/m2) | 25 ± 3 | 26 ± 4 | 0.42 |
Male, n (%) | 6 (60) | 9 (47) | 0.52 |
Duration of symptoms at time of assessment (days) | n/a | 163 [142,185] | n/a |
Heart rate (beats per minute) | 61 ± 6 | 68 ± 12 | 0.17 |
Systolic blood pressure (mmHg) | 126 ± 27 | 119 ± 17 | 0.49 |
Diastolic blood pressure (mmHg) | 70 ± 10 | 74 ± 9 | 0.30 |
Laboratory findings | |||
C-Reactive Protein at diagnosis (mg/L) | n/a | 141 ± 11 | n/a |
White Blood Cell count at study visit (109/L) | 6.4 [4.8–8.9] | 7.2 [5.9–8.6] | 0.36 |
Lymphocyte count at study visit (109/L) | 2.0 ± 0.8 | 1.0 ± 2.5 | 0.28 |
Neutrophil count at study visit (109/L) | 3.6 [2.8–5.2] | 4.4 [3.2–5.0] | 0.35 |
Monocyte count at study visit (109/L) | 0.39 ± 0.15 | 0.46 ± 0.16 | 0.30 |
Platelet count at study visit (109/L) | 226 ± 54 | 260 ± 57 | 0.14 |
Haemoglobin at study visit (g/L) | 145 [139–156] | 147 [130–150] | 0.71 |
Creatinine at study visit (µmol/L) | 66 ± 14 | 68 ± 17 | 0.69 |
eGFR at study visit (ml/min/1.73m2) | 90 [86–90] | 90 [82–90] | 0.31 |
NT-proBNP at study visit (ng/L) | 35 [35–71] | 56 [38–68] | 0.24 |
Chest X-ray findings at index diagnosis | |||
Normal, n (%) | n/a | 2(11) | n/a |
COVID-19 changes, n (%) | n/a | 3(16) | n/a |
Chest X-ray findings at ≥ 12 weeks | |||
Normal, n (%) | n/a | 4(21) | n/a |
COVID-19 changes, n (%) | n/a | 0(0) | n/a |
Cardiovascular symptoms | |||
Fatigue, n (%) | n/a | 16 (84) | n/a |
Chest pain, n (%) | n/a | 2 (11) | n/a |
Dyspnoea, n (%) | n/a | 10 (53) | n/a |
Palpitations, n (%) | n/a | 13 (69) | n/a |